New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
07:20 EDTONTYOncothyreon price target lowered to $4 from $11 at Cantor
Cantor reduced its price target on Oncothyreon as the firm believes that the company's Stimuvax drug is no longer a commercial candidate. However, the firm believes that Oncothyreon's cancer treatment PX-866, along with its cash, could be worth about $3.90 per share. The firm maintains a Buy rating on the stock.
News For ONTY From The Last 14 Days
Check below for free stories on ONTY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
06:13 EDTONTYOncothyreon announces Merck KGaA initiation of Phase 3 START2 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use